189
Participants
Start Date
June 7, 2012
Primary Completion Date
December 31, 2013
Study Completion Date
January 2, 2014
Solifenacin Succinate Suspension
Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
Placebo
Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
Urotherapy
Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
Site: 3850, Kiev
Site: 6301, Quezon City
Site: 3202, Antwerp
Site: 3209, Antwerp
Site: 3205, Leuven
Site: 5202, Mexico City
Site: 4504, Køge
Site: 4701, Bergen
Site: 3208, Charleroi
Site: 4502, Kolding
Site: 9001, Ankara
Site: 4702, Trondheim
Site: 2703, Cape Town
Site: 4501, Aarhus N
Site: 3204, Kortrijk
Site: 3201, Ghent
Site: 3203, Ghent
Site: 4602, Stockholm
Site: 1015, Albany
Site: 3812, Novi Sad
Site: 9002, Izmir
Site: 4606, Gothenburg
Site: 3853, Dnipropetrovsk
Site: 4603, Skövde
Site: 4601, Jönköping
Site: 1006, Shreveport
Site: 4605, Umeå
Site: 8207, Seoul
Site: 8201, Seoul
Site:8202, Seoul
Site:8203, Daegu
Site: 5507, Campinas
Site: 5506, Curitiba
Site: 1005, Hamilton
Site: 1001, Québec
Site: 4503, Aalborg
Site: 5205, Mexico City
Site: 4805, Gdansk
Site: 4803, Gdansk
Site: 4804, Lubin
Site: 4801, Warsaw
Site: 3810, Belgrade
Site: 8206, Incheon
Site: 3854, Kharkiv
Site: 4403, Leeds
Site: 4401, Sheffield
Astellas Pharma Europe B.V.
INDUSTRY